Linkage analyses of cannabis dependence, craving, and withdrawal in the San Francisco family study by Ehlers, Cindy L. et al.
Linkage analyses of cannabis dependence, craving, and
withdrawal in the San Francisco Family Study
Cindy L. Ehlers1, Ian R. Gizer2, Cassandra Vieten3, and Kirk C. Wilhelmsen2
1 Department of Molecular and Integrative Neurosciences, The Scripps Research Institute, La
Jolla, California
2Department of Genetics and Neurology and the Bowles Center for Alcohol Studies, University of
North Carolina, Chapel Hill, North Carolina
3 California Pacific Medical Center Research Institute, San Francisco, California
Abstract
Cannabis is the most widely used illicit drug in the United States. There is ample evidence that
cannabis use has a heritable component, yet the genes underlying cannabis use disorders are yet to
be completely identified. This study's aims were to map susceptibility loci for cannabis use and
dependence and two narrower cannabis-related phenotypes of “craving” and “withdrawal” using a
family study design. Participants were 2524 adults participating in the University of California
San Francisco (UCSF) Family Alcoholism Study. DSM-IV diagnoses of cannabis dependence, as
well as indices of cannabis craving and withdrawal, were obtained using a modified version of the
Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA). Genotypes were
determined for a panel of 791 microsatellite polymorphisms. Multipoint variance component LOD
scores were obtained using SOLAR. Genome-wide significance for linkage (LOD > 3.0) was not
found for the DSM-IV cannabis dependence diagnosis, however, linkage analyses of cannabis
“craving” and the cannabis withdrawal symptom of “nervous, tense, restless or irritable” revealed
five sites with LOD scores over 3.0 on chromosomes 1, 3, 6, 7, 9. These results identify new
regions of the genome associated with cannabis use phenotypes as well as corroborate the
importance of several chromosome regions highlighted in previous linkage analyses for other
substance dependence phenotypes.
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Introduction
National epidemiological samples have demonstrated that cannabis is the most commonly
used illicit drug [Anthony et al., 1994; Stinson et al., 2005, 2006], and that its use has
substantially increased over the last decade [Compton et al., 2004]. Chronic use of cannabis
is associated with both physical and mental health problems. Persistent use poses health
problems similar to those of tobacco [Taylor et al., 2000; Mittleman et al., 2001; Fisher et
al., 2005; Hashibe et al., 2005; Tashkin, 2005]. Cannabis use has also been implicated in a
syndrome characterized by apathy, loss of goal-directed behavior, and cognitive impairment




Am J Med Genet B Neuropsychiatr Genet. Author manuscript; available in PMC 2011 April 5.
Published in final edited form as:













termed the “amotivational syndrome” [Sharma, 1975; Pope et al., 2001; Solowij et al., 2002;
Schuckit, 2006]. Cannabis use is associated with psychotic illness and depression
[Degenhardt et al., 2003; Hall et al., 2004], as well as impaired educational and work
performance [Kandel and Chen, 2000; Lynskey and Hall, 2000; Swift et al., 2001; Schuckit,
2006]. Use of cannabis, particularly by adolescents and young adults, may also facilitate
progression to other illicit drug use (the “gateway” drug hypothesis) [Fergusson and
Horwood, 2000; Lynskey et al., 2003].
Twin and family studies have consistently found that cannabis use and use disorders appear
to in part have a genetic basis [for review see Agrawal and Lynskey, 2006]. Studies that
have evaluated the role of genetic and environmental risk factors on cannabis abuse or
cannabis dependence in twin samples have found estimates of heritability that range from
0.45 to 0.78 [see Kendler and Prescott, 1998; Tsuang et al., 1998; van den Bree et al., 1998;
Maes et al., 1999; Kendler et al., 2000, McGue et al., 2000; Miles et al., 2001; Rhee et al.,
2003]. Taken together, these studies suggest that there are substantial heritable influences on
cannabis use disorders and that studies aimed at identifying genes that contribute to cannabis
involvement may be warranted.
Disorders of cannabis use may be influenced by a number of genes that are difficult to detect
because they may each have a small effect on the broad clinical phenotype. However, the
genes influencing cannabis use disorders might be detected if they have a major effect on
more narrowly defined phenotypes that more closely index the biological processes
associated with addiction. Several biologically based theories have been suggested to
explain the compulsion to use addictive drugs that might be profitably used to develop
phenotypes useful for the study of cannabis use disorders. A general theory of addiction
posits that the neurobiological mechanisms underlying the homeostatic regulation of
appetitive drives and instincts becomes dysregulated during the process of drug exposure
[Koob, 2000]. Some measures of the strength of this process include an increase or strong
desire to take the drug often called ‘drug craving’ [see Anton, 1999], and ultimately the
development of tolerance to and withdrawal from use of the drug [Schuckit, 1995]. Some
studies have shown that requiring the presence of craving and withdrawal for the diagnosis
of alcohol dependence leads to a better diagnostic distinction between abuse and dependence
[De Bruijn et al., 2004]. In the case of cannabis dependence, recent data from large national
epidemiologic samples have confirmed that cannabis withdrawal is prevalent, correlated
with more symptoms of dependence, and associated with significant distress and impairment
[Agrawal et al., 2008c; Hasin et al., 2008].
A few studies have conducted linkage analyses using cannabis dependence, cannabis
dependence symptoms, and cannabis dependence subtypes as phenotypes [see Hopfer et al.,
2007; Agrawal et al., 2008a,b; Ehlers et al., 2009], and some significant loci have been
identified. Yet no studies to date have conducted linkage analyses using cannabis
withdrawal and/or craving phenotypes. The aim of the present set of analyses was to identify
loci associated with cannabis dependence, withdrawal and craving in the UCSF Family
Alcoholism Study. The UCSF Family Alcoholism Study is a project that was designed to
identify genetic loci that influence susceptibility to alcohol dependence and related
phenotypes. It used a small family design, focusing primarily on sibling pairs and parent-
child trios. The study enrolled 2454 individuals from 970 families from December 1995
through January 2003. Test-retest and inter-rater reliability for clinical data have been shown
to be very good [Vieten et al., 2004]. Design, methods, recruitment strategies and sample
demographics of the UCSF Family Alcoholism Study have been presented previously [see
Seaton et al., 2004; Vieten et al., 2004], along with intrafamilial correlations for primary
diagnostic phenotypes.
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The UCSF family study recruited probands with lifetime DSM-IV alcohol dependence and
the relatives of those probands, nation-wide. In addition, a community sample was
ascertained in order to estimate population means and standard deviations for heritability
and linkage analyses. Participants were recruited through the use of semi-targeted direct
mail, a web site, press releases and advertisements and from alumni of treatment centers
across the nation. Probands were invited to participate if they met screening criteria for
alcohol dependence at some point in their lifetime and had at least one sibling or both
parents available to participate in the study. With the permission of the proband, relatives
were invited by mail to participate.
Probands reporting serious drug dependence (defined as use of stimulants, cocaine, or
opiates daily for more than three months or weekly for more than six months), and those
who reported any history of intravenous substance use were excluded. Probands were
excluded if, upon screening, they reported a current or past diagnosis of schizophrenia,
bipolar disorder, or other psychiatric illness involving psychotic symptoms (those with
depressive and anxiety disorders were accepted); a life-threatening illness; or an inability to
speak and read English.
Two thousand one hundred and fifty-four individuals were enrolled in the UCSF Family
Alcoholism Study. The sample had a mean age of 48.8 ± 13.2 years, a mean educational
level of 14.4 ± 2.9 years, and a mean annual income of $57,356 ± $54,656 (median,
$45,000). Racial distribution was 92% Caucasian, 3% each African American and Hispanic,
and 1% each Native American and other. No attempt was made to exclude or over sample
minorities. Probands were 58% female. Relatives of probands were 38% alcohol dependent.
An unselected general population sample of 147 individuals was also recruited to assess
phenotype base rates. Letters were sent to residents of the same geographical areas as the
family samples, requesting participation in a study on “health behaviors and characteristics”
to avoid a sample biased toward participation in a study on alcoholism. No inclusion/
exclusion criteria were applied aside from the ability to respond to the telephone interview
and complete the questionnaires. The details of recruitment of all participants have been
previously published [see Seaton et al., 2004; Veiten et al., 2004].
Clinical measures and diagnoses
A remote data collection procedure was developed allowing for blood samples and other
questionnaires to be returned by mail, and structured diagnostic interviews to be conducted
by telephone, making nationwide data collection possible. Potential participants first had the
study explained and gave written informed consent. A modified version of the Semi-
Structured Assessment for the Genetics of Alcoholism (SSAGA) [Bucholz et al., 1994] was
used to collect demographic, medical, psychiatric, alcohol, nicotine, cannabis, and other
drug use history. The SSAGA is a fully structured, poly-diagnostic psychiatric interview that
has undergone both reliability and validity testing. Modifications of the SSAGA for the
present study included changes in diagnostic criteria and items to approximate DSM-IV
criteria. Only the sections of the SSAGA relevant to substance abuse, demographics and
medical history were utilized. We have previously demonstrated that a number of cannabis
usage phenotypes are significantly heritable including: having ever used cannabis, used
more than 21 times in a single year, DSM-IV cannabis dependence, individual criteria of
DSM-IV cannabis dependence [Ehlers et al., unpublished work]. Two phenotypes with the
highest heritability were cannabis “craving” and withdrawal. Therefore, the phenotypes
chosen for the present linkage analyses were: (1) a DSM-IV cannabis dependence diagnosis;
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(2) cannabis “craving” defined as endorsing: “In situations where you couldn't use
marijuana, did you ever have such a strong desire for it that you couldn't think of anything
else”; and (3) a measure of cannabis withdrawal defined as: “Did stopping or cutting down
after a period of regular use of marijuana ever cause you to feel nervous, tense, restless or
irritable”. The number of participants with each phenotype, with and without co-morbid
alcohol dependence, is presented in table 1. Twenty percent of those enrolled did not
complete all study requirements. Details of the interview process and inter-rater reliability of
the SSAGA in this study have been reported previously [Vieten et al., 2004].
DNA collection and genotyping
The DNA extraction procedure and genotyping protocol have been previously described
[Wilhelmsen et al., 2003]. Briefly, DNA was isolated from whole blood using a commercial
kit (Gentra, Minneapolis, MN), and genotypes for a panel of microsatellite polymorphisms
were generated using fluorescently labeled polymerase chain reaction (PCR) primers (HD5,
version 2.0; Applied Biosystems, Foster City, CA). The HD5 panel set consisted of 811
markers with an average marker-to-marker distance of 4.6 cM (maximum, 14 cM) and an
average heterozygosity of greater than 77%. A small subset of markers was omitted from the
panel because of null alleles, irregular allele spacing or other problems with reproducibility.
None of the omitted markers were adjacent to other omitted markers. The sizes of the PCR
products for the markers were determined from electropherograms produced with an ABI
3700 (Applied Biosystems, Foster City, CA), a 96-channel capillary electrophoresis device.
The sizes of marker amplimers were determined (blinded to pedigree structure and subject
characteristics) from the electropherogram using the Genotyper software package (ABI). All
electropherograms were visually inspected and exported from Genotyper in base pair sizes
relative to the standard measured to one hundredth of a base pair. Fragment sizes were
binned to alleles by using an automated algorithm developed by one of the authors
(K.C.W.), which assumes that the distribution of allele sizes will have a sine-squared
distribution with a fitted periodicity near two base pairs. The program determines the best
periodicity and phase for the modeled distribution relative to the observed distribution.
Fragments that are distributed between minimums of the modeled distribution are assumed
to be the same allele. Allele frequencies observed in the founders were used for all analysis.
The sex-averaged marker map order obtained from the manufacturer was used and verified
with the family data from the current sample.
The genotypes for all of the autosomal markers were analyzed for each family by using
Pedigree Relationship Statistical Test (PREST) [see McPeek and Sun, 2000] to detect
sample and pedigree structure errors. DNA was re-isolated from a stored frozen blood
specimen, and the genotyping was repeated for any individual for whom PREST detected a
probable error. If regenotyping failed to resolve the error, the problematic genotype was
subsequently treated as missing. The program Pedcheck was used to detect non-Mendelian
inheritance [O'Connell et al., 1998]. Markers with a high frequency of Mendelian
segregation errors were excluded from analysis, and for isolated Mendelian errors, the
genotypes for the entire family were excluded for the specific marker that yielded the error.
To further reduce errors, the probability that each genotype was correct was assessed by
using the error-checking algorithm implemented in Merlin [Abecasis et al., 2002], in which
genotypes that had a probability of less than 0.025 of being correct were removed from
further consideration.
Data analyses
Both genotype and phenotype data were available for 1647 individuals, and phenotype but
not genotype data was available for an additional 720 individuals. Of these 720 individual
Ehlers et al. Page 4













87 were relatives that could not b e contacted or did not provide DNA samples and 462 were
probands that did not provide a sufficient number of genetically informative relatives for
inclusion and the remaining 171 subjects were the relatives of these probands. Seven
hundred and thirteen families were considered genetically informative for the heritability
analyses. Families that contained sibling, half-sibling, avuncular or cousin pairs were
included as being potentially genetically informative. These families ranged in size from 3
to 20 subjects (average 4.63 ± 2.13). The data includes: 563 parent-child, 1085 sibling, 40
half-sibling, 17 grandparent-grandchild, 238 avuncular, and 32 cousin relative pairs. An
additional 177 families contained only a single individual with phenotype data. These
individuals were included within some analyses to the extent that they contribute
information about trait means and variance and the impact of covariates.
Analyses were previously conducted to estimate the heritability of the three phenotypes of
interest: DSM-IV cannabis dependence, cannabis craving, and irritable/anxious during
cannabis withdrawal using SOLAR [http://solar.sfbrgenetics.org/] [Almasy and Blangero,
1998] [Ehlers et al., unpublished work]. Participant's age at the time of evaluation and sex
were evaluated as potential covariates and retained if they accounted for at least 5% of the
total variance. The total additive genetic heritability (h2) and its standard error were
estimated, and the probability that h2 was greater than zero was determined using a Student's
t-test for each scale, and all three phenotypes were found to be heritable and as such suitable
for linkage analyses.
The variance components method implemented in SOLAR [http://solar.sfbrgenetics.org/]
was then used to calculate multipoint LOD scores across the genome at 1 cM intervals for
the three cannabis phenotypes. All traits were analyzed under a continuous trait model rather
than using the latent threshold model as the former approach provided a more conservative
estimate of linkage in the present study. A LOD threshold of 3.0 was used to identify loci
that provided evidence for linkage, and a LOD threshold of 2.0 was used to identify loci
yielding suggestive evidence of linkage. For each reported linkage peak, simulation analyses
were then conducted using SOLAR to derive nominal p-values. Specifically, a genetic locus
was simulated under the null hypothesis of no linkage across 20,000 trials, and the
distribution of LOD scores across those trials was used to derive a nominal p-value for the
observed LOD score.
Because the current sample was selected for alcohol dependence, it should be noted that
prevalence rates for the cannabis dependence diagnoses and respective symptoms in the
unselected control sample were estimated and included in the tested models to correct for
ascertainment bias when calculating h2 and linkage. In addition, the high marker density of
the HD5 microsatellite panel allows for the extraction of a large proportion of IBD
information among relative pairs as participants' genotypes can be almost completely
phased, thus reducing the reliance on population allele frequencies to estimate allele-sharing
probabilities. As a result, and given the very low number of ethnic minority participants in




The demographic characteristics of this population have been presented previously [see
Vieten et al., 2004]. In brief, the UCSF family sample had a mean age of 48.4 ± 13.4 years,
a mean educational level of 14.4 ± 2.9 years, and an annual income of $57,356 ± $54,656.
Racial distribution was: 92% Caucasian, 3% each African American and Hispanic, and 1%
each Native American and other. Fifty-four percent were married. Probands were 58%
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female, with 97% of probands meeting lifetime criteria for alcohol dependence, whereas,
38% of the relatives of probands were found to be alcohol dependent. The random sample
had similar demographic characteristics to the Family Study sample with 15% having a
lifetime history of DSM-IV alcohol dependence. The prevalence rates for DSM-IV lifetime
cannabis dependence were .16 for probands and .07 for the random sample. Prevalence rates
for cannabis withdrawal and cannabis craving were .09 in the probands and .03 in the
random sample.
Linkage analyses
Analyses of multipoint variance component LOD scores for the dichotomous DSM-IV
cannabis dependence phenotype did not yield any peaks that achieved genome-wide
significance. However, two sites were identified with LOD scores over 2.0, a site on
chromosome 1 between 142 and 159 cM with a peak at 154 cM (LOD = 2.1), and a site on
chromosome 2 between 194 and 216 cM with a peak at 211 cM (LOD = 2.6). These findings
are presented in Figure 1 and Table 2.
Linkage analyses of cannabis “craving” e.g. endorsing: “In situations where you couldn't use
marijuana, did you ever have such a strong desire for it that you couldn't think of anything
else” and the cannabis withdrawal symptom of: “Did stopping or cutting down after a period
of regular use of marijuana ever cause you to feel nervous, tense, restless or irritable”
revealed 5 sites with LOD scores over 3.0. The symptom of cannabis craving yielded the
strongest evidence for linkage (LOD = 5.7) on chromosome 7 between 70 and 83 cM with a
peak at 79 cM. At that same site there was suggestive evidence of linkage within that same
support interval with a peak at 71 cM for the withdrawal phenotype (LOD = 2.2) as
illustrated in Figure 2.
The symptom of cannabis craving also yielded strong evidence for linkage on chromosome
3 between 164 and 176 cM with a peak at 171 cM (LOD = 4.4). There was additional
evidence for linkage for cannabis craving on chromosome 1 between 36 and 48 cM with a
peak at 43 cM (LOD = 3.6), and on chromosome 6 between 195 an 202 cM with a peak at
202 cM (LOD = 3.2). There was suggestive evidence on chromosome 9 between 25 an 44
cM with a peak at 35 cM (LOD = 2.6), and on chromosome 15 between 75 and 84 cM with
a peak at 81 cM (LOD = 2.3).
The symptom “nervous, tense, restless or irritable” during cannabis withdrawal also
demonstrated evidence for linkage on chromosome 9 between 167 and 177 cM with a peak
at 174 cM (LOD = 3.6). Additionally, suggestive evidence for linkage for this withdrawal
phenotype was found on chromosome 3 between 89 and 102 cM with a peak at 96 cM (LOD
= 2.5) and on chromosome 7 between 65 and 90 cM with a peak at 71cM (LOD = 2.2) (see
Table 2 for complete results). Nominal p-values generated by simulation analyses are
presented for all three cannabis phenotypes in table 3.
Secondary analyses were conducted in order to determine whether these genome locations
were specific only to the “nervous, tense, restless or irritable” symptom of withdrawal or
whether the “sleeplessness” and a “number of withdrawal symptoms count” phenotype
could also produce similar LOD scores in those locations. Evidence for linkage on
chromosome 9 was found for the “sleeplessness” phenotype at 158 cM (LOD = 4.2) and the
symptom count phenotype (LOD = 3.2). Additionally, suggestive evidence for linkage for
the sleeplessness (LOD = 2.6) and symptom count (LOD = 3.0) phenotype was found on
chromosome 3 with a peak at 95 cM. Thus it appears that similar regions in the genome may
harbor genes for several withdrawal symptoms.
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In order to determine whether the sites identified for the cannabis phenotypes were mainly
due to comorbid alcohol dependence a separate linkage analysis was conducted using
alcohol dependence as a covariate and few differences were found. The results of those
analyses are presented in table 4. The linkage results for cannabis dependence, craving and
withdrawal were also compared to the results obtained from previous linkage scans for
alcohol and nicotine dependence that were also conducted in the UCSF family study
population. None of the linkage regions reported in a previous linkage scan for alcohol
dependence [Gizer et al., 2009] yielded neither significant nor suggestive linkage in a
subsequent scan for nicotine dependence [Gizer et al., unpublished work] in the UCSF
family study population. However, in the present set of analyses, suggestive evidence for
linkage to cannabis dependence was found at a site on chromosome 2 previously identified
in a scan for nicotine dependence [Gizer et al., unpublished work], and another site
identified for cannabis craving on chromosome 9 in the present study was also identified in a
previous scan for alcohol dependence [Gizer et al., 2009] in the UCSF family study
population. These results provide evidence suggesting that two of the regions identified in
the present set of analyses may also confer risk towards nicotine and alcohol dependence in
this population.
Discussion
Several studies suggest that there is a moderate genetic influence on cannabis dependence,
and recently there have been additional reports that have identified regions in the genome
that may be linked to cannabis dependence [see Kendler and Prescott, 1998; Tsuang et al.,
1998; Maes et al., 1999; Miles et al., 2001; Lynskey et al., 2002; Kendler et al., 2003; Rhee
et al., 2003; Wilhelmsen and Ehlers, 2005; Agrawal and Lynskey, 2006; Hopfer et al., 2007;
Agrawal et al., 2008a,b]. Only two sites, one on chromosome 1 and one on chromosome 2,
were identified in the present study for DSM-IV cannabis dependence. The site on
chromosome 1 at 154 cM (LOD = 2.1) does not appear to be within 30 cM of other sites
identified using substance dependence phenotypes. However, this peak was between two
sites; one at around 197 cM that was identified by Dick et al. [2002] in the Collaborative
Study for the Genetics of Alcoholism (COGA) dataset for a quantitative alcohol-related
phenotype and one at around 102 cM for a cannabis problems factor score in an autosomal
linkage scan for cannabis use disorders in the nicotine addiction genetics project [Agrawal et
al, 2008a].
The site identified on chromosome 2 near 211 cM (LOD = 2.6) for DSM-IV cannabis
dependence in the UCSF Family Alcoholism Study appears to be in the same general region
(within 30 cM) as a site identified in the COGA dataset for comorbid alcohol dependence
and major depression [Nurnberger et al., 2001], and for subjective response to alcohol
[Schuckit et al., 2001] using microsatellite markers and for alcohol dependence using SNP
genotyping [Agrawal et al., 2008d]. It also appears to be near a site for alcohol dependence
identified in multiplex families in Pittsburgh [Hill et al., 2004], and for heavy cocaine use
[Gelernter et al., 2005] and opioid dependence [Gelernter et al., 2006] in African Americans.
Additionally, this site was identified by a previous genome scan for nicotine dependence in
the UCSF family study [Gizer et al., unpublished work]. Thus, this site appears to harbor
genes that confer risk for a number of different substance-related phenotypes.
It has been suggested that the effort to identify genetic factors and the mechanisms whereby
they influence addiction may be aided by the use of phenotypes that may be more closely
related to the biological processes underlying risk for use disorders [Gottesman and Gould,
2003]. One phenotype that most DSM-IV substance dependence syndromes have in
common is a withdrawal syndrome defined as a combination of physiologic and
psychological processes that occurs after cessation of its use [Edwards, 1986; Weisbeck et
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al., 1996; Hasin et al., 2006, 2008]. Although withdrawal is not required to meet DSM-IV
criteria for drug/alcohol dependence it is associated with a more severe clinical course and a
poorer prognosis [Schuckit et al., 1999; Budney et al., 1999, 2003, 2004, 2008; Budney and
Hughes, 2006; Hasin et al., 2000, 2008; Ehlers et al., 2004a]; and as such, has been shown to
be more heritable than the clinical diagnosis itself in some populations [Ehlers et al., 2004b].
Another phenotype that is common to many drugs of abuse is craving. Human and animal
studies have demonstrated that craving is an important element in the addictive process and
that control of craving may improve efforts at abstinence [see Wise, 1988; Robinson and
Berridge, 1993; Anton, 1999; Sinha and O'Malley, 1999; Field et al., 2004; Heishman and
Singleton, 2006; Haughey et al., 2008]. Evaluation of the heritability of cannabis withdrawal
(h2 =0.28, p<0.001) and craving (h2 =0.36, p<0.0001) demonstrated that these two
phenotypes were more heritable than the DSM-IV diagnosis of cannabis dependence (h2
=0.20, p<0.0001) in the UCSF family study population [Ehlers et al, unpublished work].
Additionally, five sites in the genome that provided evidence for linkage to these phenotypes
were identified.
Two of the chromosome sites that were identified in the UCSF family study population for
cannabis craving and cannabis withdrawal were on chromosomes 3q and 9q. These locations
have been identified previously in genome scans for cannabis and other drug dependence
phenotypes [see Stallings et al., 2003, 2005; Hopfer et al., 2007]. Hopfer and colleagues
[2007] conducted a genome wide scan for loci influencing adolescent cannabis dependence
symptoms in 324 sibling pairs from 192 families. In that study, probands (52.1% of whom
were EuroAmerican, 36.5% of whom were Hispanic, and 7.8% of whom were African-
American) were identified from consecutive admissions to substance abuse treatment
facilities. The authors found evidence for suggestive linkage on chromosomes 3q21 (LOD =
2.61) and 9q34 (LOD = 2.57). Using the same population of adolescents, Stallings et al.
[2003, 2005], conducted linkage scans for the average number of dependence symptoms,
conduct disorder symptoms and a composite index of antisocial substance dependence, and
also found evidence for linkage to the chromosome 9q34 region (LOD = 3.15) and
3q24-3q25 (LOD = 3.27) for the composite index. The site on chromosome 3q was within
30 cM of a site identified for antisocial personality disorder/conduct disorder in an American
Indian community [Ehlers et al., 2008]. The site identified on chromosome 3q for cannabis
craving in the UCSF family study (LOD = 4.5) was also within 30 cM of the site identified
on that chromosome by Stallings et al. [2005]. Additionally, a site on chromosome 9q
(LOD=3.5) for cannabis withdrawal in the UCSF family study was also within 30 cM of the
site identified on that chromosome by Stallings et al. [2005]. Additionally, a site on
chromosome 9q (LOD=3.5) for cannabis withdrawal in the UCSF family study was also
within 30 cM of the site identified on that chromosome by Stallings et al., [2005]. Taken
together these findings suggest that these sites on chromosome 3q and 9q may harbor genes
that confer risk for severe phenotypes associated with drug dependence including antisocial
symptoms.
The region of the genome that provided the best evidence for linkage in the UCSF family
study was on chromosome 7q (LOD = 5.6) for the cannabis craving phenotype. This region
has consistently emerged with significant evidence of linkage in the COGA project. In the
initial COGA sample this region on chromosome 7q provided the strongest evidence of
linkage to alcohol dependence with a multipoint LOD score of 3.49 [Reich et al., 1998]. An
additional linkage analysis with expanded microsatellite markers in the full COGA sample
revealed a LOD score of 2.9 [Wang et al., 2004], and a set of SNPs genotyped in the region
that were not in linkage disequilibrium with adjacent markers generated a LOD score at the
peak of 4.1 [Dunn et al., 2005]. Other population samples have also found evidence for
linkage on 7q. A report of linkage to this region on 7q has been made by the Nicotine
Addiction Genetics project for alcohol consumption phenotypes [Agrawal et al., 2008a], and
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for alcohol dependence in a sample of multiplex families ascertained at Pittsburgh [Hill et
al., 2004]. A systematic SNP screen to fine map this region on chromosome 7 using the
COGA dataset identified an association with ACN9 a gene involved in gluconeogenesis and
the assimilation of ethanol or acetate into carbohydrate [Dick et al., 2008].
There were several areas of the genome that were reported previously as being linked to
cannabis use that were not identified in the current linkage scan for cannabis dependence
phenotypes in the UCSF Family study. For instance, Agrawal and colleagues [2008d]
conducted a linkage scan in a sample from the COGA study for six DSM-IV cannabis
dependence criteria considered as a continuous variable (0-6) and found a maximum LOD
score of 1.9 at 95 cM on chromosome 14. A site on chromosome 14 at 122 cM was also
found for a severe cannabis subtype generated by a cluster analysis in an American Indian
community [Ehlers et al., 2009]. This region on chromosome 14 was also identified
previously in a genome-wide linkage analysis for ASPD/CD in that American Indian
community [Ehlers et al., 2008]. Two areas of the genome were also identified in that
American Indian community study with LOD scores that provide evidence for linkage for a
severe cannabis use/antisocial subtype on chromosome 16 (@139 cM, LOD score = 4.4),
and on chromosome 19 (@74 cM, LOD score = 6.4) [Ehlers et al., 2009]. There have also
been some findings in genome scans for cannabis dependence and other drug use related
phenotypes on chromosome 19. A region has been identified on chromosome 19 at 17 cM
for early-onset cannabis use, and for frequency of use on chromosome 18, in a study of 2314
Australian families [Agrawal et al., 2008b]. A site on chromosome 4 for a cannabis
problems factor score has been identified on chromosome 4 in the region of the gamma
aminobutyric acid type A gene cluser with a LOD score of 2.2 in the Nicotine Addiction
Genetics Project [Agrawal et al., 2008a].
In summary, data from the UCSF Family study did not reveal evidence for genome-wide
significance for linkage (LOD > 3.0) to the DSM-IV cannabis dependence diagnosis,
however, linkage analyses of cannabis “craving” and the cannabis withdrawal symptom of
“nervous, tense, restless or irritable” revealed five sites with LOD scores over 3.0 on
chromosomes 1, 3, 6, 7, 9. These results have identified new regions of the genome
associated with cannabis use phenotypes as well as corroborated the importance of several
chromosome regions highlighted in previous linkage analyses for other substance
dependence phenotypes. The results of this study should, however, be interpreted in the
context of several limitations. First, multiple phenotypes were tested in the present study,
thus increasing the possibility that a false positive result was interpreted as substantive. To
protect against this possibility, empirically-derived p-values were reported for each linkage
signal allowing for the objective evaluation of the linkage evidence. Second, the findings
may not generalize to other large studies that were not ascertained for alcoholic probands.
Third, only retrospective and cross-sectional data on cannabis use and use disorders were
assessed. Fourth, comparisons to other large samples may be limited by differences in a
number of genetic and environmentally determined variables. The exclusion criteria for this
study eliminated participants reporting serious drug dependence on stimulants, cocaine, or
opiates, current diagnosis of schizophrenia, bipolar disorder, or other psychiatric illness
involving psychotic symptoms. This exclusion was included to create a more homogeneous
sample for genetic analyses. However, this limitation reduces external validity and clinical
applicability since the co-occurrence of mental health disorders and substance abuse is
common. Additionally, this sample was comprised of almost entirely Caucasians that also
limits applicability to other ethnic groups.
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Multipoint Linkage Analysis for the Cannabis dependence (upper graph), Cannabis craving
(middle graph) and Cannabis withdrawal (lower graph) phenotypes for the entire genome.
Results for each chromosome are aligned end to end with the p terminus on the left. Log of
the Odds (LOD) score is plotted on the Y-axis. Vertical lines indicate the boundaries
between the chromosomes. The numbers above on the X-axis indicate the chromosome
number.
Ehlers et al. Page 15














Multipoint Linkage Analysis for Cannabis dependence (dotted line), Cannabis craving (solid
gray line) and Cannabis withdrawal (solid black line) phenotype for chromosome 7. The
analysis assumes a latent normally distributed variable with a threshold above which an
individual is affected. Log of the Odds (LOD) score (Y-axis) is plotted for the chromosome
location map (in centimorgans (cM), X-axis). Nearest markers to the peak are presented
within the support interval.
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Table 1
Number of subjects with and without Alcohol Dependence that were genotyped for the linkage analysis of MJ
phenotypes
No AlcDep Dx Yes AlcDep Dx Total
DSM-IV MJ Dependence 763 850 1613
MJ Withdrawal 761 850 1611
MJ Craving 754 847 1601
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Table 3
Nominal p-values for cannabis phenotypes generated by simulation analyses
Chr Loc Phenotype LOD Nominal p-value
1 43cM Cannabis craving 3.6 0.0077
154cM Cannabis Dependence 2.1 0.004
2 211cM Cannabis Dependence 2.6 0.0016
3 96cM Cannabis 2.5 0.0041
171cM Withdrawal Cannabis craving 4.4 0.0031
6 202cM Cannabis craving 3.2 0.0109
7 71cM Cannabis 2.2 0.0062
79cM Withdrawal Cannabis craving 5.7 0.0007
9 35cM Cannabis craving 3.6 0.0077
174cM Cannabis Withdrawal 3.6 0.0007
15 81cM Cannabis craving 2.3 0.0249
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